Objectives: Currently used biomarkers insufficiently discriminate between patients with systemic inflammatory response syndrome of non-infectious origin and sepsis. The aim of this study was to identify surrogate markers that distinguish between systemic inflammatory response syndrome and sepsis as well as the underlying type of infection by targeted metabolomics. Design: Retrospective analysis. Settings: Six sites of the Hellenic Sepsis Study Group and at Jena University Hospital. Patients: A total of 406 patients were analyzed: 66 fulfilling criteria for diagnosis of systemic inflammatory response syndrome, 100 for community-acquired pneumonia, 112 for urinary tract infection, 83 for intra-abdominal infection and 45 for bloodstream infection. Patients were divided into test cohort (n = 268) and confirmation cohort (n = 138). Interventions: A total of 186 metabolites were determined by liquid chromatography tandem mass spectrometry. Measurements and Main Results: Serum concentrations of most acylcarnitines, glycerophospholipids and sphingolipids were altered in sepsis compared to systemic inflammatory response syndrome. A regression model combining the sphingolipid SM C22:3 and the glycerophospholipid lysoPCaC24:0 was discovered for sepsis diagnosis with a sensitivity of 84.1% and specificity of 85.7%. Furthermore, specific metabolites could be used for the discrimination of different types of infection. The glycerophospholipid lysoPCaC26:1 identified patients with community-acquired pneumonia in sepsis or severe sepsis/septic shock. Within severe sepsis/septic shock, patients with bloodstream infection could be discriminated by a decrease of acetylornithine. Changes of metabolites between sepsis and severe sepsis/septic shock also varied according to the underlying type of infection, showing that putrescine, lysoPCaC18:0 and SM C16:1 are associated with unfavorable outcome in community-acquired pneumonia, intraabdominal infections and bloodstream infections, respectively.
Conclusions: Using a metabolomics approach, single metabolites are identified that allow a good, albeit at about 14% false positive rate of sepsis diagnosis. Additionally, metabolites might be also useful for differentiation and prognosis according to the type of underlying infection. However, confirmation of the findings in ongoing studies is mandatory before they can be applied in the development of novel diagnostic tools for the management of sepsis. (Crit Care Med 2016; 44:1649-1662) Key Words: diagnosis; metabolites; prognosis; sepsis; systemic inflammation S evere sepsis and septic shock remain the leading causes of death despite all efforts for early recognition and initiation of therapy (1, 2) . Although it is common knowledge that early management is the key to decrease mortality, current diagnostics based on biomarkers and conventional microbiology are neither rapid nor reliable (3) .
Traditionally, sepsis biomarkers are molecules produced in response to an infectious stimulus. It is assumed that circulating concentrations should reflect the severity of the inflammation and that changes should provide information regarding alterations in the physical course. Although some laboratory parameters like C-reactive protein (CRP), interleukin (IL)-6 and procalcitonin are currently broadly used in the clinical practice, none of them can perfectly discriminate an infectious from a non-infectious inflammatory process, for example, elevation of procalcitonin has been shown in several other non-infectious conditions (severe trauma and surgery) (4) . Part of the failure of these biomarkers is due to the highly individualized nature of sepsis. In a recent cohort of 505 patients from the Hellenic Sepsis Study Group (HSSG) the immunological status of the patients early upon diagnosis was analyzed by flow cytometry. Analysis indicated that the status of the host upon transition from sepsis to severe sepsis/septic shock greatly differed depending on the underlying type of infection (5) . As a consequence, it may be hypothesized that most of the biomarkers studied so far may vary in a similar fashion.
These data support the concept of individualized approaches based on high throughput technologies, such as transcriptomics, proteomics, and metabolomics (6) (7) (8) (9) (10) . In a recent targeted approach, we determined 186 metabolites in the plasma of 143 critically ill patients hospitalized in an ICU. Analysis indicated two metabolites (acylcarnitine C10:1 and glycerophospholipid PCaaC32:0) that could discriminate between systemic inflammatory response syndrome (SIRS) and severe sepsis (11) . Although this study indicated the validity of these two metabolites as a diagnostic tool, it presented several limitations since it was conducted in a cohort of critically ill patients with intra-abdominal sepsis developing postoperatively. These patients vary considerably in nature from the common outpatients and inpatients of the general ward who develop sepsis. To fully test the diagnostic value of metabolites in early sepsis recognition, a new analysis was conducted in a large cohort of patients with sepsis. The primary aim of this study was to define a metabolic profile that clearly differentiated between noninfectious SIRS and sepsis, with secondary endpoints of identifying metabolic markers that differentiate among underlying causes of infection, and finally, to identify markers that predict patient outcome.
MATERIALS AND METHODS

Study Design
This was a retrospective analysis of samples collected at six sites of the HSSG from January 2007 to January 2012 and at one site of the ICU of the Department /11 , and 0713-08/01). Every patient was enrolled after written informed consent; written consent was given by first-degree relatives for patients unable to consent. Inclusion criteria were as follows: 1) age more than 18 years old; 2) signs of SIRS developing during the last 24 hours; and 3) acute pancreatitis, severe injuries with Injury Severity Index more than 10, postoperatively from cardioaortic bypass surgery without any signs of infection despite thorough clinical and radiological work-out, community-acquired pneumonia (CAP), intra-abdominal infections (IAI), acute pyelonephritis (urinary tract infection [UTI]), or primary Gram-negative bacteremia (bloodstream infection [BSI]). Exclusion criteria were as follows: 1) neutropenia defined as less than 1,000 neutrophils per cubic millimeter; 2) infection by HIV; and 3) chronic intake of corticosteroids defined as more than 1 mg/ kg of equivalent prednisone daily for more than 1 month. Acute pancreatitis was defined by all of the following: 1) the presence of characteristic epigastric pain radiating to the back; 2) blood amylase levels three times above upper normal levels; 3) urine amylase three times above upper normal levels; 4) imaging findings on CT or abdominal ultrasound compatible with acute pancreatitis; and 5) the absence of any primary liver disease.
Classifications of SIRS and sepsis stages and diagnosis of infections were made according to international definitions (12, 13) . Ten milliliters of blood was sampled after venipuncture of one forearm vein under aseptic conditions and collected into pyrogen-free tubes within 12 hours of the advent of epigastric pain or within less than 24 hours after ICU admission or from the advent of signs of sepsis. Blood was centrifuged and serum was stored at -80°C until assayed.
CAP was diagnosed for any patient with the following: 1) no contact with healthcare facilities for the past 90 days; 2) new consolidation in chest x-ray; and 3) at least two signs of dyspnea, respiratory rales, or purulent sputum. BSI was considered as the isolation of one pathogen in the bloodstream. Isolation of coagulase-negative staphylococci and skin commensals was considered contamination and not BSI. IAI was considered as any radiological examination (ultrasound or CT) accompanying SIRS. UTI was defined as all the following: 1) dysuria; 2) pyuria (> 10 leukocytes/hpf of spunned urine); and 3) compatible ultrasound findings.
Laboratory Analysis
Concentrations of biomarkers were measured using the following: the immunoassay CRP Vario (Abbott GmbH, Ludwigshafen, Germany) for CRP; immunofluorescence KRYPTOR assay (Brahms GmbH, Hennigsdorf, Germany) for procalcitonin; and the chemoluminescence immunoassay IMMULITE (Siemens healthcare Diagnostics GmbH, Eschborn, Germany) for IL-6.
Metabolite concentrations of six analyte classes (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, sphingolipids, and sugars) were measured in serum according to the manufacturer`s protocol (AbsoluteIDQ kit p180 [Biocrates Life Science AG, Innsbruck, Austria]), as described previously (11) . Mass spectrometric analysis was performed on an API4000 liquid chromatography tandem mass spectrometry (LC-MS/MS) system (AB Sciex, Framingam, MA) equipped with an electrospray ionization source, a G1367B Agilent 1200 Series autosampler (Agilent, Santa Clara, CA), and the Analyst 1.5 software (AB Sciex). Amino acids and biogenic amines were analyzed by reversed phase LC-MS/MS (AB Sciex) and injection of 10 μL sample. The flow injection analysis-mass spectrometry/mass spectrometry method was used for the measurement of acylcarnitines, glycerophospholipids, sphingolipids, and sugars. In this method, 20 μL of the sample was injected directly, one time for positive and one time for negative mode analysis. Concentrations of metabolites were determined using the MetIQ software package, which is an integral part of the AbsoluteIDQ kit (Biocrates Life Science AG, Innsbruck, Austria). These data were exported for the following statistical analysis. Concentrations of some metabolites, especially glycerophospholipids, were determined only semiquantitatively, by using nonphysiological or similar standards. For analysis, only metabolites which appear in at least 50% of the patients were included.
Statistical Analysis
Statistics were computed with IBM SPSS Statistics 19 (IBM, New Armonk, NY). Enrolled patients were divided into one test cohort and another confirmation cohort, at a 2:1 independent randomization for each three patients for each study site. Comparisons of baseline characteristics were performed by an unpaired Student t test. After testing for normal distribution for metabolites and conventional biomarkers, either an unpaired Student t test or Mann-Whitney U test was used with "post hoc" Bonferroni adjustment for multiple comparisons to avoid random correlations. Heat maps of the metabolites were performed with the web server MetaboAnalyst (currently updated by Dr. Jeff Xia at McGill University, Montreal, Quebec, Canada) (14) . Data were normalized for each metabolite (autoscaling method, mean-centered and divided by the SD of each variable). A hierarchical clustering in the form of a dendrogram for the metabolites using the Pearson distance and the average algorithm was performed. Chi-square automatic interaction detection algorithm was used for the creation of decision trees. For the combination of analytes, a binary logistic regression analysis was performed. Sensitivities and specificities of metabolites and predicted probabilities for correct classification were plotted as receiver operating characteristic (ROC) curves. All data points were included for the ROC analysis, also outliers. Cutoff concentrations that discriminate infection from SIRS, the type of infection or that indicate fatal outcome were selected. The optimal cutoff value was calculated out of the ROC curves as the highest Youden Index value (sensitivity + specificity -1) (15) . Kaplan-Meier survival analysis was done for patients above or below specific cutoffs for fatal outcome followed by log-rank comparisons. Boxplots were generated according to standard definitions: bold lines depict median values, boxes interquartile ranges (IQRs), and whiskers extreme values within the 2.5-fold IQR around the median.
RESULTS
Patient Groups
From a total of 420 patients screened for eligibility, 406 patients were enrolled: 268 as a test cohort and 138 as a confirmation cohort ( Fig. 1) of patients in the confirmation cohort was 10 (7.2%), 7 (5.1%), 7 (5.1%), 33 (23.9%), 39 (28.2%), 23 (16.7%), and 19 (13.8%). The two cohorts were similar regarding demographics and disease severity ( Table 1) .
Metabolite Changes in Relation to Sepsis
The primary endpoint of this study was to define those metabolites that can clearly differentiate between SIRS and sepsis. To have a SIRS group which reflects the heterogeneous composition of patients with non-infectious systemic inflammation, we included three different SIRS cohorts: patients with pancreatitis, patients with SIRS following traumatic injury, and patients with SIRS following cardiac surgery. Between these three SIRS cohorts, we observed large differences in all measured metabolite classes ( Supplementary Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/B825). The majority of significant different metabolites affecting all metabolite classes (eight acylcarnitines, 14 amino acids, seven biogenic amines, 60 glycerophospholipids, and eight sphingolipids) are increased in pancreatitis compared to SIRS following traumatic injury or cardiac surgery. Ten short-and medium-chain acylcarnitines, the amino acid glutamine, four biogenic amines, three glycerophospholipids, two sphingolipids, and sugar showed lower concentrations in patients with pancreatitis. In addition, some metabolites were decreased (three acylcarnitines, five biogenic amines, 12 glycerophospholipids, and sugar) or increased (two biogenic amines and four glycerophospholipids) in patients with SIRS following cardiac surgery compared to patients with SIRS following traumatic injury. This demonstrates the heterogeneity of the SIRS patient group according to their different etiologies, but did not exclude potential bias due to different preanalytical conditions at the different study sites. In a recent publication from our group, an extensive metabolomic approach was conducted in 74 patients with severe SIRS and in 69 patients with severe sepsis/septic shock. Two main metabolites (PCaaC32:0 and C10:1) were identified that could efficiently discriminate between severe SIRS and severe sepsis/septic shock (sensitivity, 73.3%; specificity, 84.8% ) (11) . We first validated the discriminatory potential of the combination of these two metabolites in a binary logistic regression in the current cohort, for the discrimination of patients with severe SIRS and severe sepsis/septic shock, providing a sensitivity of 89.2% and specificity of 73.5%. However, after the addition of uncomplicated SIRS and sepsis cases, a lower sensitivity of 85.0% and specificity of 60.6% were observed in the merged cohort. Thus, other metabolites were examined for their discriminatory power.
By comparing all patients with non-infectious SIRS of different etiology with the sepsis cohort, 11 analytes were found to be increased and 15 analytes were decreased in sepsis compared to SIRS in the test cohort ( Fig. 2A) . The variations of these 26 significant different metabolites, comprising three acylcarnitines; three amino acids; five biogenic amines; eight glycerophospholipids; and seven sphingolipids, are visualized in a heat map (Fig. 2D) . The selection of new metabolomic biomarkers, for inclusion in a binary logistic regression analysis, was performed by a decision tree analysis, only containing those metabolites which are significantly different after Bonferroni correction (data not shown). From this analysis, the sphingolipid SM C22:3 (area under the curve [AUC], 0.796 [95% CI, 0.708-0.885]) and the glycerophospholipid lysoPCaC24:0 (AUC, 0.700 [95% CI, 0.590-0.810]) were chosen for binary logistic regression, calculating the predictive probability for the presence of sepsis.
The AUC of the ROC curves obtained indicated a better discriminatory effect of the combination of SM C22:3 and lysoPCaC24:0 (AUC, 0.9 [95% CI, 0.839-0.962]; cutoff, 0.983) compared to CRP (AUC, 0.743 [95% CI, 0.658-0.827]; p = 0.000131), procalcitonin (AUC, 0.615 [95% CI, 0.506-0.724]; p < 0.000001), or IL-6 (AUC, 0.578 [95% CI, 0.454-0.702]; p < 0.000001) (Fig. 2, B and C) . A combination of the three conventional markers does not lead to an increased discriminatory potential compared with the metabolomic model (AUC, 0.747 [95% CI, 0.667-0.826]; p = 0.000174). Using the combined marker SM C22:3 and lysoPCaC24:0 for the diagnosis of sepsis results in a sensitivity of 84.1% and specificity of 85.7%.
Metabolite Changes in Relation to the Underlying Type of Infection
One endpoint of this study was to characterize the change of metabolite concentrations according to the type of infection. This type of analysis indicated a great heterogeneity from one infection to the other. Figure 3 visualizes these variations between different types of infection in a heat map for sepsis ( Fig. 3A, left) and severe sepsis/septic shock (Fig. 3B, left) .
In sepsis, 14 glycerophospholipids decreased and two glycerophospholipids and four acylcarnitines increased within patients who were suffering from CAP compared to patients with other types of infection. Interestingly, no differences were found between patients with IAIs, UTIs, and BSIs (Supplementary Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/B825). The metabolites with the best p values were selected and the cutoffs were determined using a ROC curve. The glycerophospholipid lysoPCaC26:1 (Fig. 3A, right) allows the discrimination of patients due to CAP from patients of other etiologies of sepsis with high sensitivity and specificity (AUC, 0.818 [95% CI, 0.687-0.948]; sensitivity, 76.9%; specificity, 98.9%; positive predictive value, 95.2%; negative predictive value, 94.1%).
In case of severe sepsis/septic shock, we observed an increase of three acylcarnitines, two glycerophospholipid, and four sphingolipids and a decrease of two acylcarnitines and the glycerophospholipid PCaaC34:3 in patients with CAP, compared to IAI, UTI, and BSI (Supplementary Table 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/ B825). Again lysoPCaC26:1 (Fig. 3B, right) Furthermore, in contrast to sepsis, in the event of severe sepsis/septic shock, metabolites were also different in patients with IAIs, UTIs, and BSIs. Specifically, three glycerophospholipids were increased in patients with severe UTI compared to patients with severe IAI. Patients with severe UTI showed higher concentrations of the acylcarnitine C18:1, two biogenic amines, six glycerophospholipids, and two sphingolipids and lower concentrations of two glycerophospholipids in comparison to patients with severe BSI. Higher concentrations of the acylcarnitine C2 and the biogenic amine acetylornithine and lower concentrations of the acylcarnitine C18:1-OH and the glycerophospholipid lysoPCaC26:1 could be observed in patients with severe IAI in relation to patients with severe BSI. The biogenic amine acetylornithine was indicative for the exclusion of severe BSI (AUC, 0.853 [95% CI, 0.757-0.948]; cutoff, 0.697 μM; sensitivity, 93.8%; specificity, 71.7%; positive predictive value, 53.6%; negative predictive value, 97.1%).
Metabolites as Prognostic Markers
Based on previous findings of the HSSG showing that the innate and adaptive immune responses differed between sepsis and severe sepsis/septic shock depending on the underlying type of infection (5) , we compared the metabolome between sepsis and severe sepsis/septic shock separately for each type of infection. This type of analysis indicated a great heterogeneity, depending on the type of infection (Fig. 4A) . More precisely, when sepsis is compared to severe sepsis/ septic shock in the event of CAP, putrescine is increased, as well as the glycerophospholipid PCaeC34:1. In the event of IAIs, comparison of sepsis with severe sepsis/septic shock is accompanied by an increase of the biogenic amine symmetric dimethyl arginine (SDMA) and by a decrease of six glycerophospholipids. In the event of BSI, comparison with severe sepsis/septic shock is accompanied by a decrease of 26 glycerophospholipids and of nine sphingolipids. Interestingly, no differences were found between sepsis and severe sepsis/septic shock in patients with UTIs.
The described heterogeneity between sepsis and severe sepsis/septic shock, between the different types of infection, prompted us to select one metabolite per type of infection to be used as a prognostic marker of the final outcome. Metabolites with the lowest p value of significance between sepsis and severe sepsis/septic shock after Bonferroni correction were selected as predictors for unfavorable outcome. These were the biogenic amine putrescine for patients with CAP, the glycerophospholipid lysoPCaC18:0 for patients with IAI and the sphingolipid SM C16:1 for patients with BSI (Fig. 4B) . No significant metabolite could be identified for the discrimination of patients with sepsis and severe sepsis/septic shock caused by UTIs. A prognostic cutoff concentration to predict the unfavorable outcome was selected after ROC analysis. The relationship of these cutoff concentrations with unfavorable outcome was proven after Kaplan-Meier analysis and showed that concentrations of putrescine above 0.072 μΜ for patients with CAP (AUC, 0.774 [95% CI, 0.657-0.892]), of lysoPCaC18:0 below 12.23 μM for patients with IAIs (AUC, 0.858 [95% CI, 0.755-0.961]), and of SM C16:1 below 17.57 μM for patients with BSI (AUC, 0.975 [95% CI, 0.920-1.000]) are predictors of unfavorable outcome (Fig. 4, C-E) .
Confirmation of the Analysis
The confirmation cohort of 138 patients was analyzed independently to test two aspects: 1) whether the use of the combination of SM C22:3 and lysoPCaC24:0 can discriminate between SIRS and sepsis and 2) whether the identified metabolites are capable for the differentiation of the underlying type of infection and identification of patients with unfavorable outcome. The study endpoints were almost confirmed ( Table 2) . When used in the confirmation cohort, the sensitivity and specificity values of the combination of SM C22:3 and lysoPCaC24:0 to discriminate between SIRS and sepsis were 85.1% and 87.5%, respectively.
DISCUSSION
The human metabolome is subject to continuous modifications. Here, we present a targeted approach to identify characteristic changes in the serum metabolome in septic patients with different types of infection. We could show that the combination of two metabolites (SM C22:3 and lysoPCaC24:0) can effectively discriminate sepsis from SIRS (test and confirmation cohort: 84.1%/85.1% sensitivity, 85.7%/87.5% specificity, respectively). Current findings also indicate the need to follow a differentiated approach for biomarker application in sepsis; metabolites can be used to discriminate according to the type of infection and final outcome.
Experience with even the highest-ranking biomarkers suggests that they cannot differentiate sepsis caused by infection from other etiologies of systemic inflammation with sufficient sensitivity and specificity (16) . In particular, they fail to discriminate between SIRS and uncomplicated sepsis (i.e., infection without organ failure) (17) . In contrast, the combination of the metabolites SM C22:3 and lysoPCaC24:0 presented here allow for discrimination between SIRS and even the less severe cases of sepsis. Most of the metabolites measured were down-regulated in sepsis compared to SIRS, particularly acylcarnitines, glycerophospholipids, and sphingolipids. Several studies conducted in humans have described alterations in lipid metabolism during the course of sepsis. Findings suggest a reduction in circulating levels of lipoproteins, particularly of high-density lipoprotein (HDL), low-density lipoprotein, and phospholipids and an increase of free cholesterol and triglycerides (the so-called lipemia of sepsis) (18, 19) . During infection and inflammation, there are also changes in lipoprotein composition and thus in function. The most impressive modifications in HDL are an abrupt increase in serum amyloid A (SAA) and secretory non-pancreatic phospholipase A 2 (sPLA 2 ) (20) . SAA seems to be involved in the neutralization of lipopolysaccharide (LPS) as an LPS binding protein or by increasing macrophage-mediated LPS uptake (21, 22) . It is assumed that the increase in SAA content in HDL is a mechanism for the decreased HDL level (23) . Acute phase SAA-rich HDL is also known to activate sPLA 2 , which was reported to release oxidized fatty acids from HDL which lead to highly pro-inflammatory and pro-atherogenic properties (24, 25) . Oxidized lipids seem to have a protective function during sepsis (26) . Acylcarnitines were considerably altered in our patient populations, a finding consistent with our previous study on 69 patients with severe sepsis/septic shock (11) , a recent large systemic metabolomics approach for the prediction of death in sepsis (27) , and a recent integrative omics approach in primates that was validated also in human patient cohorts (28) . These findings suggest impaired mitochondrial function which is a common characteristic in sepsis partly due to tissue hypoperfusion (29) . Individualized patterns of the metabolome are described for the first time herein in relation to the underlying type of infection. Contrary to CAP, the metabolome seems to be less broadly modulated in the case of IAI, UTI, and BSI. CAP is mainly caused by the Gram-positive Streptococcus pneumoniae that possesses completely different virulence characteristics than Gram-negative bacteria. A metabolomics approach in mice, infected by S. pneumoniae, showed that glycerophospholipids as well as putrescine are differentially regulated in liver and lung, depending on infection with either serotype 19F S. pneumonia (causing lobar pneumonia), or serotype 2 S. pneumoniae (causing septic pneumococcal disease) (30) . These animal findings strengthen the importance of the described changes of a glycerophospholipid and putrescine in CAP. Additionally, our results, showing that putrescine is associated with unfavorable outcome in CAP, are supported by recent findings from Shah et al (31) , demonstrating that polyamines are key metabolites for the growth, fitness, and virulence of S. pneumoniae.
Gram-negative bacteria are the main pathogens for UTI, IAI, and BSI (Table 1) . A former animal study indicated some compartmentalization in the pattern of lipid peroxidation in the case of Gram-negative infection (32) . More precisely, after experimental Pseudomonas aeruginosa peritonitis in rats, lipid peroxidation was up-regulated in the liver and down-regulated in the kidney. Excess lipid peroxidation in sepsis is due to the excess formation of free radicals and to the subsequent impairment of the mitochondrial electron chain (29) . This leads to the decreased biosynthesis of sphingolipids and glycerolipids in the liver explaining the findings in severe BSIs and IAIs. The reported down-regulation of lipid peroxidation in the kidney might also explain why the renal SDMA product (33) , is increased in severe sepsis/septic shock after IAIs.
In severe BSIs, concentrations of sphingolipids and phosphatidylcholines were significantly decreased. When BSI develops, the systemic circulation is exposed to high levels of endotoxins (LPS) of the outer membrane of rapidly replicating bacteria. In sepsis caused by Gram-negative bacteria, the activity of lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is elevated and this correlates with the concentration of circulating endotoxin (34) . Lp-PLA 2 rapidly hydrolyzes phosphatidylcholines into lysophospholipids. Furthermore, LPS increases the serum activity of secretory sphingomyelinase, which hydrolyzes sphingomyelin to ceramide leading to the decrease of serum sphingolipids (35) . This might explain the observed modulation of the metabolome in severe sepsis/septic shock caused by BSI.
In contrast to the observed differences between CAP and other sepsis etiologies, metabolomic profiles fail to discriminate IAIs, UTIs, and BSIs from each other in sepsis and partly in severe sepsis/septic shock. We hypothesize that this might be due to the larger amount of epithelial cells in the lung compared to other organs and the specific lipid composition of the airway epithelium (36) that might be altered differently in infectious lung diseases. Additionally, in UTIs, we also fail to discriminate patients with sepsis and severe sepsis/septic shock. In a model of experimental pyelonephritis due to the ligation of pelvo-ureteral junction and injection of community-acquired and hospital-acquired isolates of P.aeruginosa above the junction, serum concentrations of malondialdehyde failed to indicate any significant over-time changes of malondialdehyde, a product of lipid membrane peroxidation, compared with the baseline (37) . This may corroborate, at least in part, the described lack of differences in circulating metabolites between sepsis and severe sepsis/septic shock in UTIs.
The present targeted metabolomics approach allowed us to achieve all three study endpoints: 1) to provide metabolites that can clearly discriminate between non-infectious SIRS and sepsis; 2) to indicate metabolites that might be of diagnostic value depending on the nature of the underlying infection; and 3) to identify some metabolites that can provide information about the final outcome in patients based on the underlying type of infection.
However, the study has several limitations. First, the sample size of the group of patients with SIRS and some subgroups is rather small, which might have an impact on the accuracy of ROC curve analysis (38, 39) . However, since the calculated CIs for AUCs did not overlap with the reference line (AUC, 0.5) group size might be sufficient. Second, sample quality and thus the identification of sepsis biomarkers might be biased by heterogeneous preanalytical conditions at different study sites. It is well known that several preanalytical conditions, for example, sampling, transport, time to centrifugation, time to freeze, as well as sample storage, can have a major impact on sample quality and thus metabolite composition (40) (41) (42) (43) . Although we have preliminary evidence (n = 5) that relevant metabolites identified in this study are, at least at room temperature, not dependent on the time to centrifugation (Supplementary Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/B825), we cannot exclude that biomarker candidates might be influenced by a multitude of other conditions, since we assume that, for example, their cutoff values might vary depending on sample quality. Thus, it might be necessary to reevaluate cutoffs in a new prospectively collected larger sample cohort. Additionally, preanalytical bias could also favor the identification of only robust metabolites, compromising the identification of unstable, even though pathophysiological important, metabolites as biomarkers in our study. In addition, consideration of preanalytical bias is even more relevant if the different study groups are not equally distributed across the different study sites. Patients with CAP, IAI, UTI, and BSI were collected at HSSG under comparable preanalytical conditions and could not be clustered in a principal component analysis according to the study site by using the seven biomarker candidates identified (data not shown). However, patients with pancreatitis and patients with SIRS following traumatic injury/cardiac surgery were collected at HSSG and Jena University Hospital, respectively. Thus, we cannot exclude that differences in metabolites between SIRS following traumatic injury/cardiac surgery and pancreatitis as well as patients with sepsis might be biased by different preanalytical conditions; however, we can assume that the observed differences between SIRS following traumatic injury and SIRS following cardiac surgery are not due to differences in preanalytical conditions since they have been collected under the same conditions.
Third, although we could exclude that differences in age or gender confounds the findings, we cannot rule out that there are other factors, for example, therapy/support measures that might influence the results.
The presented results of this proof of principal study reveal that different metabolomic patterns exist between SIRS and sepsis and that the metabolome is differently modulated between CAP and other types of infection and between sepsis and severe sepsis/septic shock for CAP, BSI, and IAI. Thus, these findings may have a major impact on the development of novel diagnostic tools for early diagnosis and prognosis of sepsis. However, validation of the results in a larger independent prospectively collected patient cohort is mandatory to confirm their usefulness as biomarkers in the management of sepsis.
